收费全文 | 2790篇 |
免费 | 264篇 |
国内免费 | 117篇 |
耳鼻咽喉 | 17篇 |
儿科学 | 8篇 |
妇产科学 | 11篇 |
基础医学 | 100篇 |
口腔科学 | 11篇 |
临床医学 | 134篇 |
内科学 | 107篇 |
皮肤病学 | 5篇 |
神经病学 | 39篇 |
特种医学 | 61篇 |
外科学 | 67篇 |
综合类 | 349篇 |
预防医学 | 13篇 |
眼科学 | 1980篇 |
药学 | 116篇 |
中国医学 | 46篇 |
肿瘤学 | 107篇 |
2024年 | 10篇 |
2023年 | 42篇 |
2022年 | 79篇 |
2021年 | 100篇 |
2020年 | 121篇 |
2019年 | 80篇 |
2018年 | 122篇 |
2017年 | 93篇 |
2016年 | 116篇 |
2015年 | 105篇 |
2014年 | 161篇 |
2013年 | 209篇 |
2012年 | 142篇 |
2011年 | 194篇 |
2010年 | 168篇 |
2009年 | 186篇 |
2008年 | 191篇 |
2007年 | 205篇 |
2006年 | 183篇 |
2005年 | 149篇 |
2004年 | 106篇 |
2003年 | 79篇 |
2002年 | 66篇 |
2001年 | 44篇 |
2000年 | 30篇 |
1999年 | 23篇 |
1998年 | 24篇 |
1997年 | 16篇 |
1996年 | 10篇 |
1995年 | 12篇 |
1994年 | 7篇 |
1993年 | 6篇 |
1992年 | 4篇 |
1991年 | 6篇 |
1990年 | 2篇 |
1989年 | 3篇 |
1988年 | 7篇 |
1987年 | 3篇 |
1986年 | 8篇 |
1985年 | 12篇 |
1984年 | 13篇 |
1983年 | 6篇 |
1982年 | 5篇 |
1981年 | 7篇 |
1980年 | 8篇 |
1978年 | 2篇 |
1977年 | 1篇 |
1974年 | 2篇 |
1972年 | 1篇 |
1970年 | 1篇 |
Aims:
To represent the effects of transpupillary thermotherapy (TTT) and intravitreal bevacizumab on choroidal metastases and review the literature.Settings and Design:
A retrospective, interventional, noncomparative case series.Materials and Methods:
A retrospective, interventional, noncomparative case series of five eyes in three patients with choroidal metastases was conducted. Fundus findings of choroidal metastases were divided into two types: Solitary or diffuse type. The size of the tumor was termed small (<10 mm diameter), medium (10–15 mm diameter) or large (>15 mm diameter). All eyes received one session of TTT followed by 3 weekly intravitreal bevacizumab injections as an adjuvant therapy. The parameters of treatment for TTT were 1.2–3 mm spot size, 150–300 mW, 60 s with the whole lesion covered confluently. The changes in preoperative and postoperative best-corrected visual acuity (BCVA) were recorded. Serial color fundus photography and optical coherent tomography were performed to measure the treatment efficacy.Results:
All eight choroidal metastases were solitary type. The size of six tumors was small, the size of one tumor was medium, and the size of one tumor was large. All five eyes of the three patients had improvement of BCVA after treatment. Fundus photos revealed tumor shrinkage and the mean shrinkage percentage was 61.27 ± 21.71%. Optical coherence tomography revealed complete resolution of serous retinal detachment. There was no recurrence after 6 months follow-up.Conclusions:
TTT combined with intravitreal bevacizumab injections brought about beneficial effects in reducing tumor size and improving vision in all five eyes of the three patients. Despite the retrospective nature of our study, the absence of control group and the size limitation that, of course, limit the statistical power, TTT combined with intravitreal bevacizumab seems to be efficient in providing another cost-reducing and time-saving treatment option for patients with choroidal metastases. The antineoplastic properties of bevacizumab make it a viable adjunctive therapy. Studies with more cases and a longer follow-up period are warranted. 相似文献Purpose:
The effect of hypothyroidism on the choroidal thickness (CT) was investigated in patients with subclinical hypothyroidism and overt hypothyroidism, and biochemically and clinically euthyroid patients receiving levothyroxine treatment. The patients were compared with healthy subjects.Materials and Methods:
One eye of 71 hypothyroid and 22 healthy subjects between 20 and 40 years of age were included in this study. CT measurements were taken at the fovea and at 2 points that were 1500 μm nasal and temporal to the fovea using spectral-domain optical coherence tomography. Independent sample t-test''s and was used for statistical analysis of the data.Results:
The CT was significantly thicker in hypothyroid patients compared to healthy subjects (P values were 0.013 for subfoveal, 0.015 for temporal and 0.020 for nasal segments). The intraocular pressure (IOP) and body mass index (BMI) were also significantly higher in hypothyroid patients (P values were 0.021 and 0.003, respectively). There was not a statistically significant difference in the BMI and IOP measurements between healthy subjects and euthyroid patients (P > 0.05). However, there was a statistically significant difference in the subfoveal, temporal and nasal CT measurements between healthy subjects and euthyroid patients (P values were 0.006, 0.031 and 0.013, respectively).Conclusions:
All subgroups of hypothyroid patients had thicker CT compared to healthy subjects. Euthyroid patients receiving levothyroxine treatment had lower IOP, BMI levels, and serum lipid levels than patients with subclinical hypothyroidism and overt hypothyroidism. 相似文献方法:将符合纳入标准,经吲哚青绿脉络膜血管造影(indocyanine green angiography, ICGA)、光学相干断层扫描( optical coherence tomography, OCT)检查确诊为黄斑区脉络膜新生血管( CNV)患者27例27眼,经PDT治疗后3~7 d内行 ranibizumab 玻璃体腔注射。观察治疗后1,3,6 mo、末次随访时行最佳矫正视力、FFA、ICGA、OCT 检查及有无并发症发生情况。
结果:最佳矫正视力提高17眼(63%),最佳矫正视力稳定6眼(22%),最佳矫正视力下降4眼(15%)。27例27眼治疗前平均渗漏面积为1005.69±105.47μm,治疗后1,3mo后平均875.54±103.27,423.37±79.68μm,与治疗前比较差异有统计学意义(P<0.01),视网膜黄斑中央厚度27例27眼治疗前平均厚度为485.58±122.59μm,治疗后1,3mo后平均398.84±105.32,297.74±89.18μm,与治疗前比较差异有统计学意义(P<0.01)。
结论:PDT 封闭 CNV 后,联合玻璃体内腔内注射ranibizumab,有效阻断新生血管复发,减少PDT再次治疗次数和并发症,可提高治疗效果。 相似文献
方法:以pSilencer2.1-U6neo为质粒载体,构建HIF-1α.siRNA 重组质粒。选取雄性Sprague-Dawley(SD)大鼠54只,随机分为正常对照组(15只)和实验组(39只)。实验组采用尾静脉注射链尿佐菌素(STZ)的方法建立糖尿病大鼠模型,造模成功后将实验组随机分为糖尿病组(15只)、基因治疗组(12只)和空载体组(12只)。正常对照组及糖尿病组大鼠均不做转染; 基因治疗组和空载体组分别转染HIF-1α.siRNA 重组质粒和pSilencer空载体质粒。行苏木精-伊红染色(hematoxylin-eosin staining,HE染色)观察视网膜组织形态,并采用免疫组织化学法检测VEGF蛋白的表达。分别于干扰后24、48、72h,1wk时计算VEGF蛋白的抑制效率。采用单因素方差分析和LSD-t检验进行统计学分析。
结果:HIF-1α.siRNA 重组质粒经酶切、测序鉴定,确定为目的序列。HE染色显示:正常对照组大鼠视网膜各层细胞排列整齐,细胞形态基本正常。糖尿病大鼠视网膜各层细胞排列紊乱,内界膜不完整,新生血管芽、新生血管簇呈垂直状突破内界膜生长。免疫组织化学染色显示:VEGF阳性表达为细胞浆出现棕黄色颗粒,主要位于神经节细胞层。正常对照组VEGF蛋白呈弱阳性表达,而DR对照组和空载体组表达明显增强,基因治疗组较DR组和空载体组表达明显减少,差异有统计学意义(P<0.05)。VEGF蛋白抑制率24、48、72h和1wk时分别为:27.4%、40.6%、47.5%、64.5%。
结论:HIF-1α.siRNA重组质粒能够抑制糖尿病大鼠视网膜中VEGF蛋白的表达,可能成为一种治疗糖尿病性新生血管疾病的新方法。 相似文献
视网膜新生血管性疾病是致盲的主要原因。趋化因子受体7(C-C chemokine receptor type 7, CCR7)可通过细胞外信号调节激酶(extracellular signal regulate kinase,ERK)通路促进血管内皮生长因子(vascular endothelial growth factor, VEGF)的表达,导致血管渗漏、血管内皮细胞增生以及新生血管形成等改变。趋化因子受体7的检测可指导视网膜新生血管性疾病的诊治。 相似文献